HCW11-006

HCW11-006 is a preclinical, novel multi-functional immune cell stimulator developed using the TRBC (T-cell Receptor Binding Complex) drug discovery and development platform by HCW Biologics. It is a recombinant protein-based immunotherapy designed to induce potent anti-tumor CD8+ T cell and natural killer (NK) cell responses without triggering unwanted side effects, as demonstrated in relevant solid tumor animal models. The molecule combines several different immune functional domains to enhance anti-tumor immunity and is part of a new class of compounds aimed at disrupting the link between inflammation and age-related diseases, including cancer. The drug has been licensed to WY Biotech for global development (excluding certain territories), with both companies collaborating on its advancement for in vivo therapeutic applications[1][3][4][6].